# EDGAR Filing Document

**Accession Number:** 0001878313
**File Stem:** 0001564590-23-001566
**Filing Date:** 2023-2
**Character Count:** 2279
**Document Hash:** 476edb3bb1e68db2af35cfb44e902c09
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001564590-23-001566.hdr.sgml**: 20230522

**ACCESSION NUMBER**: 0001564590-23-001566

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230207

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MAIA Biotechnology, Inc.
- **CENTRAL INDEX KEY:** 0001878313
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 444 WEST LAKE STREET, SUITE 1700
- **CITY:** CHICAGO
- **STATE:** IL
- **ZIP:** 60606
- **BUSINESS PHONE:** 312-416-8592

**MAIL ADDRESS:**
- **STREET 1:** 444 WEST LAKE STREET, SUITE 1700
- **CITY:** CHICAGO
- **STATE:** IL
- **ZIP:** 60606

#### MAIA Biotechnology, Inc.

#### 4444 West Lake Street, Suite 1700

#### Chicago, IL 60606
February 7, 2023

#### VIA EDGAR & TELECOPY
U.S. Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

Washington, D.C. 20549

Attention: Jimmy McNamara

---

| | |
|:---|:---|
| **RE:**  | **MAIA Biotechnology, Inc. (the "Company")** |
|  | **Registration Statement on Form S-1 (File No. 333-269606) (the "Registration Statement")**<br> **<u>Request for Acceleration of Effective Date</u>**<br>|

---

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended (the "Act"), the Company requests that the Securities and Exchange Commission (the "Commission") take appropriate action to cause the Registration Statement become effective on February 8, 2023 at 5:00 p.m., Eastern Time, or as soon as practicable thereafter, or at such later time as the Company or its counsel may request via telephone call to the staff. In making this acceleration request, the Company acknowledges that it is aware of its obligations under the Act.

---

| | | |
|:---|:---|:---|
| Very truly yours,**<br>MAIA Biotechnology, Inc.** | Very truly yours,**<br>MAIA Biotechnology, Inc.** | Very truly yours,**<br>MAIA Biotechnology, Inc.** |
| By:  | /s/ Vlad Vitoc | /s/ Vlad Vitoc |
|  | Name:  | Vlad Vitoc |
|  | Title: | Chief Executive Officer |

---

cc: Angela Dowd, Esq., Loeb & Loeb LLP